Researchers at NYU School of Medicine have identified a target for slowing the progression of multiple myeloma by using currently available drugs.

- Glenmark's first novel molecule for an oncology indication - GBR 401 is a monoclonal antibody targeting CD19.

Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive non-Hodgkin's lymphoma that accounts for approximately 40 percent of lymphomas among adults.

NEW YORK, Sept. 21 /PRNewswire/ -- While general awareness of lymphoma remains high, a new survey released today by the Lymphoma Research Foundation (LRF) reveals significant knowledge gaps among Americans about the disease, which is the most prevalent form of blood cancer in the United States.

SAN DIEGO, June 22 /PRNewswire/ -- Nereus Pharmaceuticals, Inc., a pioneer in drug discovery and development from marine microbial sources, announced completion of enrollment in the randomized Phase 2 ADVANCE study evaluating its tumor selective vascular disrupting agent (VDA), plinabulin (NPI-2358), in patients with non-small cell lung cancer (NSCLC) who have failed treatment with chemotherapy.